Brief: Candel Therapeutics Announces Restructuring To Prioritize Resources On Key Value Drivers For Expanded Development Of Can-3110
28/11/2023 15:32
Nov 28 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS ANNOUNCES RESTRUCTURING TO PRIORITIZE
RESOURCES ON KEY VALUE DRIVERS FOR EXPANDED DEVELOPMENT OF
CAN-3110, THE ENLIGHTEN™ DISCOVERY PLATFORM, AND KEY CLINICAL
READOUTS FOR CAN-2409
* CANDEL THERAPEUTICS INC: REDUCING COMPANY'S WORKFORCE AND
EXPENSES ASSOCIATED WITH ENABLING COMMERCIAL READINESS OF
CAN-2409
* CANDEL THERAPEUTICS INC - DECREASES WORKFORCE BY
APPROXIMATELY
50%
* CANDEL THERAPEUTICS INC - EXTENDS CASH RUNWAY INTO Q4 OF
2024
Source text for Eikon: ID:nGNX4Z1Zh
Further company coverage: CADL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec